Nutriband

Nutriband Inc. is a US-based biopharmaceutical company focused on developing and commercializing advanced transdermal drug delivery technologies. Its strategic achievements include the acquisition of clinical subsidiary 4P Therapeutics, establishing a robust patent portfolio for its flagship AVERSA abuse-deterrent platform, and building a hybrid business model with contract manufacturing and consumer product revenue streams. The company's strategy is to first bring an abuse-deterrent fentanyl patch to market, followed by expanding the AVERSA technology to other high-risk drugs and leveraging its transdermal expertise to convert injectable biologics into patch-based therapies.

The AVERSA™ abuse-deterrent transdermal system integrates aversive agents to deter tampering and misuse of patch-based drugs, complemented by 4P Therapeutics' expertise in developing transdermal formulations for large-molecule biologics and injectables.

In abuse-deterrent transdermal patches, Nutriband's AVERSA platform appears unique with its patent portfolio, though it may face future competition from large pharma. In broad transdermal delivery, it competes with established firms and biotechs, where success hinges on demonstrating superior efficacy in delivering large molecules like biologics.